AEON Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AEON Biopharma, Inc. on August 3, 2026. The filing addresses the Company's regulatory status regarding its listing on the NYSE American exchange.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes
On August 3, 2026, the Company received confirmation from NYSE Regulation that it has regained compliance with the continued listing standards of NYSE American. Specifically, the Company resolved previously identified deficiencies under Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide.
Outlook, Risks, and Management Commentary
- Trading Symbol Update: The Company expects the "below compliance" (.BC) indicator to be removed from its Class A common stock trading symbol (AEON).
- Listing Status: The Company anticipates removal from the NYSE American list of noncompliant issuers.
- Ongoing Obligations: The Company remains subject to continued listing standards and could face further action if it falls below any standard again.
- Risk Factors: Forward-looking statements regarding continued compliance are subject to risks detailed in the Company's Form 10-K for the year ended December 31, 2025.
Investor Verification Checklist
- Confirm the removal of the ".BC" indicator from the AEON trading symbol on NYSE American.
- Verify the Company's removal from the NYSE American noncompliant issuers list.
- Review the Form 10-K filed on March 30, 2026, for updated risk factors affecting future compliance.
- Monitor future filings for any recurrence of listing standard deficiencies.